Home / Business and Economy / GSK India Profit Soars 15.7% on Strong Vaccine and Drug Demand
GSK India Profit Soars 15.7% on Strong Vaccine and Drug Demand
3 Aug
Summary
- First-quarter profit increased by 15.7% to 2.37 billion rupees.
- Revenue from operations saw a 16.6% rise, reaching 9.38 billion rupees.
- New drug approvals for multiple myeloma and respiratory disease are anticipated.
GlaxoSmithKline Pharmaceuticals India announced a robust first-quarter performance, with profits climbing 15.7% year-on-year to 2.37 billion rupees. The company’s financial results, reported on Monday, reflect a strong demand for its comprehensive range of vaccines, respiratory medicines, and specialty drugs.
Revenue from operations experienced a healthy increase of 16.6%, totaling 9.38 billion rupees. This growth is attributed to the consistent performance across its drug and vaccine portfolio. The company highlighted its commitment to innovation and future expansion.
Looking ahead, GlaxoSmithKline India is preparing to launch Blenrep, a treatment for adults with relapsed or refractory multiple myeloma. Additionally, marketing authorization has been secured for Arexvy, a vaccine designed to prevent lower respiratory tract disease in older adults and specific high-risk individuals.
Analysts view these developments positively, noting that the expanding global specialty pipeline enhances long-term growth prospects for Glaxo India. The company is actively transitioning towards a more innovation-driven product offering.
